Compare CRNX & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | PD |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 636.9M |
| IPO Year | 2018 | 2019 |
| Metric | CRNX | PD |
|---|---|---|
| Price | $35.31 | $7.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $76.75 | $12.63 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 416.95 |
| EPS | N/A | ★ 1.87 |
| Revenue | $1,039,000.00 | ★ $492,546,000.00 |
| Revenue This Year | $720.10 | $3.58 |
| Revenue Next Year | $184.67 | $2.88 |
| P/E Ratio | ★ N/A | $3.62 |
| Revenue Growth | N/A | ★ 5.36 |
| 52 Week Low | $25.83 | $5.70 |
| 52 Week High | $57.99 | $17.45 |
| Indicator | CRNX | PD |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 52.93 |
| Support Level | $33.19 | $6.01 |
| Resistance Level | $44.18 | $7.91 |
| Average True Range (ATR) | 2.31 | 0.37 |
| MACD | -0.44 | -0.02 |
| Stochastic Oscillator | 3.32 | 45.13 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.